Mission Statement:
The Foundation for Angelman Syndrome Therapeutics Australia (or FAST) is an organization of families and professionals dedicated to finding a cure for
Angelman Syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy. The Foundation is
committed to assisting individuals living with Angelman Syndrome to realize their full potential and quality of life.
We are confident that our goals are now within reach and together, with your help, we will change lives. You are our driving force,
please
donate generously and bring us one step closer to realizing our mission.
Our People:
Setting out on the mission to cure a genetic disorder requires the concerted efforts of a diverse, dedicated group of individuals.
With leaders in the field of science, medicine, business, technology and entertainment, the Foundation for Angelman Syndrome
Therapeutics is well poised to realize its mission.
Board of Directors:
Our Board of Directors utilize their expertise in various fields to advance our mission, assess our strategies and create opportunities
to aggressively pursue our goals.
Meet the Board of Directors
Scientific Advisory Board:
The Scientific Advisory Board (or SAB) consists of nationally and internationally recognized clinicians and scientists considered experts
in their respective fields. Specific disciplines represented by the SAB include; pediatric neurology, epilepsy, diet and nutrition,
human neurodevelopment, human cognitive disorders, small animal behavior, animal models of human disorders, mechanisms of learning and
memory, synaptic plasticity and function, cellular signal transduction, cellular protein trafficking, epigenetics and genetics.
Meet the SAB
Transparency:
As a non-profit organization, the Foundation for Angelman Syndrome Therapeutics realizes that transparency is vitally important to our members.
This section will provide a detailed view of our financial information. Currently there are no financials since FAST Australia was established in May 2010.